RecruitingPhase 3NCT05677971

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Takeda
Principal Investigator: Study Director
Takeda
Intervention: Fazirsiran Injection(drug)
Enrollment: 160 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2023 – 2030

Study locations (30)

University of Alabama at Birmingham, Birmingham, Alabama, United States
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
Mayo Clinic, Phoenix, Arizona, United States
University of Arizona Thomas D. Boyer Liver Institute, Tucson, Arizona, United States
Gastroenterology & Liver Institute, Escondido, California, United States
University of California San Diego, Altman Clinical and Translational Institute, La Jolla, California, United States
UCLA Pulmonary and Critical Care, Los Angeles, California, United States
Stanford University, Palo Alto, California, United States
University of California Benioff Children's Hospital, San Francisco, California, United States
Peak Gastroenterology Associates, PC, Colorado Springs, Colorado, United States
University of Florida, Gainesville, Florida, United States
Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Indiana University School of Medicine - Indianapolis, Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
+15 more locations on ClinicalTrials.gov

Collaborators

Takeda Development Center Americas, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05677971 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials